Biotech and Money are pleased to announce the release of the latest Drugs & Dealers Magazine. This is issue 10 of the bi-monthly publication aimed at providing insight, foresight and hindsight to life science executives involved in funding, investment, partnering and deal making.

Here’s what you can expect to read from the digitally interactive 10th issue:

• University of Oxford Exosome spin-out excites investors: Fresh from their successful £10m seed fund raise from Oxford Science Innovation, we talk to the CEO of Evox Therapeutics, Prof. Matthew Wood about their exciting exosome technology and future plans now that the investment has been secured.
• Securing follow-on funding and investment: DefiniGEN CEO Marcus Yeo talks to Biotech and Money about his approach to securing follow-on funding from existing notable investors plus the potential their iPSC production and metabolic disease modelling holds.
• Enlarged Amryt Pharma joins AIM after reverse takeover: Joe Wiley, the CEO of Amryt Pharma a speciality pharma company focused on Orphan Disease, outlines the process behind their reverse takeover which led them to listing on AIM and successfully tapping public markets for £10m.
• Acquiring companies with realisable commercial technology: New acquisition vehicle Levrett Plc comes online and immediately targets promising and realisable pharma and biotech technology. Here we talk to CEO Pascal Hughes on how and where the business will take advantage.
• Placements, clinical studies and the utility of Parsotix: Andrew Newland, the CEO of ANGLE Plc, a commercially driven specialist medical diagnostic company recently raised £10.2m in a placement on AIM. We discuss the lessons learned and what we can expect to see from their exciting Parsotix technology.
• Syndicating for a £19m Series A financing: We find time with Paolo Paoletti, CEO of Kesios Therapeutics, a company with a promising multiple myeloma offering and a rising star in the UK biotech field, to discuss fund raising and the current level of ambition.
• Innovative cancer detection and the £11m IPO: Oncimmume, a leading UK early cancer detection company recently secured AIM listing and an £11m IPO. Here we talk to CEO Geoffrey Hamilton-Fairley on the successful process and what that now means for growth.
• The Brexit Referendum Result: John Rountree, Managing Partner of Novasecta, a specialist pharmaceutical management consulting firm, provides their perspective on the implications for pharma and biotech.
• Biotech and Money Assembly & Awards Dinner: The Biotech and Money Assembly and Awards Gala Dinner is a 300+ person, C-Suite evening function that affords its attendees premier networking combined with some unique touches to make it a must attend.